Septerna Inc. Common Stock (SEPN)
Stock · NASDAQ · Health Care
$36.35as of 10/16/2026
Price chart
Active signals
SEPN Signal Track Record
How signals performed across all stocks →What SEPN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 10 | -0.1% | 50% | October 7, 2026 |
| Bollinger Band Breakout | 8 | +8.1% | 63% | August 4, 2026 |
| Bollinger Band Breakdown | 4 | +29.3% | 75% | October 6, 2026 |
| Any 20-session window (baseline) | +5.1% | 63% |
Computed by MarketWall from daily closing prices since August 14, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric m…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 123
- Website
- septerna.com/
Fundamentals
- 1-day range
- $34.66$37.09
- Market cap
- $1.78B
- P/E (trailing)
- —
- P/E (forward)
- -19.01
- EPS (trailing)
- $-0.54
- Dividend yield
- —
- Beta
- 0.70
- Avg. volume
- 390.5K
How Septerna Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Septerna Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SEPNSepterna Inc. Common Stock$36.35▼ 2.94%Market cap $1.78BP/E —$17.55$51.1
- GENBGenerate Biomedicines Inc. Common Stock$12.09▼ 7.43%Market cap $1.78BP/E —$11$22.67
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
- SRPTSarepta Therapeutics Inc. Common Stock (DE)$17.1▼ 3.88%Market cap $1.77BP/E —$14.68$24.68
- SNDXSyndax Pharmaceuticals Inc. Common Stock$12.9▼ 5.49%Market cap $1.76BP/E —$12.99$25.59
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- PRGOPerrigo Company plc Ordinary Shares$16.63▲ 0.91%Market cap $1.74BP/E —$9.23$22.02
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SEPN Septerna Inc. Common Stock | $1.78B | — | $36.35 | ▼ 2.94% | $17.55$51.1 |
| GENB Generate Biomedicines Inc. Common Stock | $1.78B | — | $12.09 | ▼ 7.43% | $11$22.67 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
| SRPT Sarepta Therapeutics Inc. Common Stock (DE) | $1.77B | — | $17.1 | ▼ 3.88% | $14.68$24.68 |
| SNDX Syndax Pharmaceuticals Inc. Common Stock | $1.76B | — | $12.9 | ▼ 5.49% | $12.99$25.59 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| PRGO Perrigo Company plc Ordinary Shares | $1.74B | — | $16.63 | ▲ 0.91% | $9.23$22.02 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 45.33M
- Total value held
- $1.09B
- Institutional holders
- 119
- Unknown7.00M
- Unknown6.22M
- Unknown4.40M
- Unknown4.21M
- Unknown3.15M
- Unknown2.91M
- Unknown2.00M
- Unknown1.82M
- Unknown1.35M
- Unknown1.34M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Septerna Schedules Upcoming Investor Conference Appearances
Septerna announced plans to participate in upcoming investor conferences. Such events are routine for publicly traded companies and provide opportunities for management to engage with institutional investors and analysts. The conferences may include presentations and one-on-one meetings, though no specific details about agenda topics were disclosed.
Septerna Schedules Upcoming Investor Conference Appearances. Septerna announced plans to participate in upcoming investor conferences. Such events are routine for publicly traded companies and provide opportunities for management to engage with institutional investors and analysts. The conferences may include presentations and one-on-one meetings, though no specific details about agenda topics were disclosed.